Nanoparticles for sustained release of active agents for the treatment of pulmonary hypertension
Pulmonary hypertension is a serious, lifethreatening
disorder which substantially restricts physical capacities and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated.<br> The new nanoparticles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of pharmacological effects and a considerably improved quality of patients' life.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A flexible and efficient DC power converter for sustainable-energy microgrids
A new DC-DC power converter is superior to previous designs and paves the way for more efficient, reliable and sustainable energy storage and conversion solutions. The Kobe University development can…
Technical Trials for Easing the (Cosmological) Tension
A new study sorts through models attempting to solve one of the major challenges of contemporary cosmic science, the measurement of its expansion. Thanks to the dizzying growth of cosmic…
Peptides on Interstellar Ice
A research team led by Dr Serge Krasnokutski from the Astrophysics Laboratory at the Max Planck Institute for Astronomy at the University of Jena had already demonstrated that simple peptides…
